Factor XII
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='7fbp' size='340' side='right' caption='Glycosylated human factor XII protease domain (grey) | + | <StructureSection load='7fbp' size='340' side='right' caption='Glycosylated human factor XII protease domain (grey) complex with cyclic peptide inhibitor (green)' scene='91/916250/Cv/1'> |
== Function == | == Function == | ||
| Line 11: | Line 11: | ||
== Relevance == | == Relevance == | ||
| - | Inhibition of the FXII-driven contact system may be a promising therapeutic anticoagulation treatment strategy<ref>PMID:27834692</ref>. | + | Inhibition of the FXII-driven contact system may be a promising therapeutic anticoagulation treatment strategy<ref>PMID:27834692</ref>. The choice of cyclic peptides as inhibitors of FXIIa is based on their being cell-permeable and more stable to proteolysis. |
== Structural highlights == | == Structural highlights == | ||
Revision as of 10:44, 4 July 2022
| |||||||||||
References
- ↑ Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood. 2012 Nov 22;120(22):4296-303. doi: 10.1182/blood-2012-07-292094. Epub 2012, Sep 19. PMID:22993391 doi:http://dx.doi.org/10.1182/blood-2012-07-292094
- ↑ Nickel KF, Long AT, Fuchs TA, Butler LM, Renne T. Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases. Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):13-20. doi:, 10.1161/ATVBAHA.116.308595. Epub 2016 Nov 10. PMID:27834692 doi:http://dx.doi.org/10.1161/ATVBAHA.116.308595
- ↑ Liu W, de Veer SJ, Huang YH, Sengoku T, Okada C, Ogata K, Zdenek CN, Fry BG, Swedberg JE, Passioura T, Craik DJ, Suga H. An Ultrapotent and Selective Cyclic Peptide Inhibitor of Human beta-Factor XIIa in a Cyclotide Scaffold. J Am Chem Soc. 2021 Nov 10;143(44):18481-18489. doi: 10.1021/jacs.1c07574. Epub, 2021 Nov 1. PMID:34723512 doi:http://dx.doi.org/10.1021/jacs.1c07574
